Award
Definitive Contract #75A50122C00028
HHS Awards $322M to Boston University for Antibacterial Accelerator Program
Buyer
Office of Assistant Secretary for Preparedness and Response
Award Amount
$140,000,000.00
Ceiling
$315,000,000.00
Period of Performance
Jun 01, 2022 – May 31, 2027
Identifier
75A50122C00028
NAICS
541714
The Department of Health and Human Services (HHS) has awarded a definitive contract to Trustees of Boston University, supporting the CARB-X Global Antibacterial Accelerator project. This cost-reimbursable contract, valued at a potential total of $322,000,000, will focus on enhancing the development and evaluation of innovative antibacterial therapies to combat antibiotic-resistant infections. With a performance timeline running from June 1, 2022, to May 31, 2032, the contract emphasizes a commitment to addressing critical public health challenges posed by resistant bacteria. The contract was awarded through a full and open competition and includes no set-aside designation. Key subcontractors include Duke University, Locus Biosciences Inc., and Cellics Therapeutics Inc., each contributing vital expertise in systematic reviews, engineered bacteriophage therapies, and innovative sepsis treatments respectively. The awarded contract represents a significant investment in advancing antibacterial research and development, crucial for safeguarding public health.
Description
CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA - UPDATE PERIOD OF PERFORMANCE